Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...